DCSZ11 with radiation and chemotherapy for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called DCSZ11 combined with standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients whose cancer cells have normal DNA repair (a specific type called pMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older and in good overall health (able to do light activities)
- You have rectal cancer that has not been treated with chemotherapy or radiation before
- Your cancer is locally advanced (larger tumor or spread to lymph nodes) but has not spread to distant parts of your body
- Your heart function is normal (at least 50% ejection fraction, checked by ultrasound or scan)
- Your blood counts and organ function meet study requirements
- You are willing to use birth control during the study and for a specified period after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether combining radiation and chemotherapy with two immunotherapy drugs can better treat locally advanced rectal cancer (no spread to distant organs). It may shrink the tumor before surgery, and if you are enrolled, you will receive this combination as part of the study.
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.